Article Versions Notes

Audouard E, Khefif N, Gillet-Legrand B, Nobilleau F, Bouazizi O, Stanga S, Despres G, Alves S, Lamazière A, Cartier N, et al. Modulation of Brain Cholesterol Metabolism through CYP46A1 Overexpression for Rett Syndrome. Pharmaceutics. 2024; 16(6):756. https://doi.org/10.3390/pharmaceutics16060756

Audouard, Emilie, Nicolas Khefif, Béatrix Gillet-Legrand, Fanny Nobilleau, Ouafa Bouazizi, Serena Stanga, Gaëtan Despres, Sandro Alves, Antonin Lamazière, Nathalie Cartier, and et al. 2024. "Modulation of Brain Cholesterol Metabolism through CYP46A1 Overexpression for Rett Syndrome" Pharmaceutics 16, no. 6: 756. https://doi.org/10.3390/pharmaceutics16060756

Audouard, E., Khefif, N., Gillet-Legrand, B., Nobilleau, F., Bouazizi, O., Stanga, S., Despres, G., Alves, S., Lamazière, A., Cartier, N., & Piguet, F. (2024). Modulation of Brain Cholesterol Metabolism through CYP46A1 Overexpression for Rett Syndrome. Pharmaceutics, 16(6), 756. https://doi.org/10.3390/pharmaceutics16060756